Polpharma gets €45m EU biosimilars funding boost
This article was originally published in Scrip
Executive Summary
In an attempt to address unmet medical need in Europe in the areas of Crohn's disease, cancer, multiple sclerosis and rheumatoid arthritis, the European Investment Bank is lending Polish drug manufacturer Polpharma €45m for its biosimilars R&D.